Dr. Heidi Queen’s recent presentation on Cardiovascular Disease (CVD) Hormones and Cholesterol

Cardiovascular disease (CVD) is the leading cause of death in women, with risk accelerating rapidly post-menopause due to declining estrogen. Estrogen normally acts as a cardioprotective agent, keeping blood vessels flexible and maintaining healthy cholesterol levels (higher HDL/lower LDL). Its loss during menopause triggers, among other things, increased LDL, higher blood pressure, and increased abdominal fat.

Topics covered include:

1. Risk of Cardiovascular Disease (CVD) in Women 

• Leading Cause of Death: CVD is not just a “man’s disease”; it is the #1 killer of women, yet it is often under-recognized.
• Delayed Onset: Women generally develop CVD roughly 10 years later than men, due to natural protection from estrogen before menopause.
• Increased Risk Factors: Post-menopausal women have a 2-6 times higher incidence of CVD compared to pre-menopausal women.
• Unique Risks: Pregnancy-related issues (pre-eclampsia, gestational diabetes), autoimmune diseases, and menopause transition (hot flashes/night sweats) are considered markers of heightened CVD risk.

2. What is Cholesterol?

• Function: Cholesterol is a waxy substance produced by the liver, essential for building cells, but high levels in the blood are dangerous.
• LDL (Bad Cholesterol): Low-density lipoprotein collects in artery walls, leading to plaque buildup (atherosclerosis) and restricted blood flow.
• HDL (Good Cholesterol): High-density lipoprotein helps remove “bad” cholesterol from the bloodstream, protecting against heart disease.
• Impact of Menopause: Without estrogen, the liver produces higher total cholesterol and LDL, while HDL levels often drop.

3. How Estrogen Loss Increases CVD Risk

• Loss of Protection: Estrogen acts as a vasodilator, keeping vessels open and relaxed. Its decline leads to stiffer arteries and higher blood pressure.
• Lipid Profile Shift: Lower estrogen reduces HDL (“good”) and increases LDL (“bad”) and triglycerides, leading to faster plaque accumulation.
• Fat Redistribution: Reduced estrogen causes fat to shift from the hips/thighs to the abdomen (visceral fat), which releases inflammatory compounds.
• Insulin Resistance: The hormonal shift can increase insulin resistance, predisposing women to type 2 diabetes, a major risk factor for CVD.
• Timing Hypothesis: The rapid decline in estrogen during the perimenopausal period is a critical window, where early intervention (lifestyle or, if recommended, hormone therapy) is essential to prevent long-term damage.